Answers are grounded in this paper and cite their sources.
BACKGROUND: The phase III APPLE trial evaluated the efficacy of adding bevacizumab to atezolizumab with carboplatin plus pemetrexed (APP) for individuals with advanced nonsquamous non-small cell lung cancer (NSCLC). We here report the long-term outcomes of this trial with 3.5 years of follow-up. METHODS: Patients with advanced nonsquamous NSCLC were randomized 1:1 to receive APP or APP plus bevacizumab (APPB). Stratification factors were clinical stage, driver oncogenes, and PD-L1 expression. Endpoints included progression-free survival, overall survival (OS), and safety. RESULTS: A total of 412 patients were enrolled; 1 patient was excluded from the intention-to-treat population. Of the remaining patients, 287 patients were classified as driver oncogene-negative and 124 as driver oncogene-positive. The updated median OS was 28.0 months in the APPB arm and 25.7 months in the APP arm, with a hazard ratio (HR) of 0.88 (95% confidence interval [CI], 0.70-1.10). For the driver oncogene-negative population, the median OS was 27.6 months in the APPB arm and 27.8 months in the APP arm (HR of 0.96 [95% CI, 0.73-1.27]), with the corresponding values for the driver oncogene-positive population being 28.0 and 20.8 months (HR of 0.71 [95% CI, 0.47-1.08]). Safety profiles did not change from earlier analysis. CONCLUSIONS: The addition of bevacizumab to APP did not improve OS in patients with advanced nonsquamous NSCLC. In the driver oncogene-positive subgroup, favorable OS trend was observed in the bevacizumab arm, highlighting its potential as a treatment option for individuals who have failed molecular-targeted therapy.
No takes yet. Share an insight, caveat, or question.
Shiraishi et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: